Authors: Nataša Jovanov Milošević1, 2, Miloš Judaš1, Eleonora Aronica3,4, Ivica Kostovic1
Prog Brain Res. 2014;214:159-78. doi: 10.1016/B978-0-444-63486-3.00007-4.
The neural extracellular matrix (ECM) provides a supportive framework to differentiating cells and their processes, and regulates morphogenetic events by spatially and temporally relevant localization of signaling molecules and by direct signaling via receptor and/or co-receptor-mediated action. Embryonic and fetal human brain contains large amount and diversity of extracellular matrix components, which is especially prominent in the transient subplate zone, in the crossroads of axonal pathways, at the developing cortex-white matter interface and in the marginal zone. Perinatal and postnatal reorganization of these tissue compartments extends into the second year of life. Developmental changes in the amount and composition of the extracellular matrix (as well as changes in fibre architectonics) are significant for plastic responses to damage as well as for changes in magnetic resonance imaging (MRI) signal intensity of the fetal and early postnatal human brain.
In this chapter we discuss the expression pattern of major components of the fetal ECM of the human brain and the role they play during laminar and connectivity development in healthy brain as well as in the neurodevelopmental disorders. The aim of the chapter is to elucidate ECM-related developmental events as potential models of successful functional recovery after injury and to explore its relevance for diagnostic and therapeutic approaches.
Authors: Sadowski K. , Józwiak S.
Journal of Epileptology, 2014; 22(2):89-98
Manuscript ID: 892079
- Introduction. Epilepsy that is associated with neurocutaneous disorders seriously deteriorates quality of life and cognitive outcome of affected children. Recent advances in epilepsy pathophysiology raise hopes for better treatment results in this difficult group of patients.
- Aim. The aim of this review is to present recent treatment recommendations as well as current research progress in the most frequent neurocutaneous disorders.
- Material and methods. We analyzed PubMed database to select the most prominent and recent (up to 2014 year) publications on the treatment and mechanisms of epilepsy in selected neurocutaneous disorders. We aimed to emphasize evidence-based medicine recommendations as well as basic experimental studies dealing with molecular mechanisms of epileptogenesis.
- Discussion and conclusions. Recent advances in disease-modifying treatment options such as mTOR inhibitors in patients with tuberous sclerosis complex open up new perspectives for neurologists. Traditional resective surgery has still a major role as a treatment of choice in carefully selected cases.
Pediatric Neurology 51 (2014), pp. 758-759
Authors: Jóźwiak S, Kotulska K, Domańska-Pakieła D, Lojszczyk B, Syczewska M, Chmielewski D, Dunin-Wąsowicz D, Kmieć T, Szymkiewicz-Dangel J, Kornacka M, Kawalec W, Kuczyński D, Borkowska J, Tomaszek K, Jurkiewicz E, Respondek-Liberska M.
Eur J Paediatr Neurol. 2011 Sep;15(5):424-31. doi: 10.1016/j.ejpn.2011.03.010. Epub 2011 Apr 19.
- Background: Epilepsy appears in 70-80% of patients with tuberous sclerosis complex, most commonly in the first year of age. Early manifestation of epilepsy is associated with drug-resistant epilepsy and mental retardation in more than 80% of patients. Clinical epileptic seizures are preceded by deterioration of EEG recording thus infants with high risk of epilepsy can be identified.
- Aims: We hypothesized that preventative antiepileptic treatment of infants with multifocal activity on EEG might lower the incidence of drug-resistant epilepsy and mental retardation.
- Methods: Forty-five infants with early diagnosis of tuberous sclerosis complex were included in the open-label study. They were divided in two groups: standard (n=31) and preventative one (n=14). In standard group the antiepileptic treatment was launched early, but after the onset of seizures. In preventative group medication was commenced when active epileptic discharges were seen on EEG, but before the onset of clinical seizures. Children were followed till the end of 2 years of age.
- Results: At 24 months of age mental retardation was significantly more frequent and severe in "standard" vs "preventative" group (48% vs 14%; p=0.031; mean IQ score 68.7 vs 92.3; p<0.05). The "preventative" group was characterized by higher ratio of seizure-free patients (93% vs 35%; p=0.004), lower incidence of drug-resistant epilepsy (7% vs 42%; p=0.021) and lower number of patients requiring polytherapy (21% vs 55%; 0.039) than the "standard group.
- Conclusions: Preventative antiepileptic treatment of infants with tuberous sclerosis complex and high risk of epilepsy markedly improves their neurodevelopmental outcome and reduces the incidence of drug-resistant seizures.
Eur J Paediatr Neurol. 2012 Nov;16(6):582-6. doi: 10.1016/j.ejpn.2012.05.004. Epub 2012 Jun 12.
Tuberous sclerosis complex (TSC) is a leading genetic cause of epilepsy. TSC-associated epilepsy generally begins during the first year of life, and is associated with neurodevelopmental and cognitive problems. Management is challenging and seizures tend to persist in a large proportion of patients despite pharmacological and surgical treatment. This report summarizes the clinical recommendations for the management of TSC-associated epilepsy made by a panel of European experts in March 2012. Current treatment options and outstanding questions are outlined.